SHH and basal cell carcinoma: More recently, as a result of positive preclinical data and divergent downstream signaling through SMO, which supports an immunosuppressive TME, a phase I/II clinical trial has been initiated in basal cell carcinoma patients with the FDA-approved SHH inhibitor vismodegib in combination with the checkpoint inhibitor pembrolizumab [471].